Business Context and Reporting Period
Company: Enanta Pharmaceuticals, Inc. (ENTA)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2025
Business Overview: Enanta is a biotechnology company focused on discovering and developing small molecule drugs for virology and immunology. Its primary revenue source is royalties from AbbVie's HCV treatment, MAVYRET/MAVIRET, which contains Enanta's protease inhibitor, glecaprevir. The company is advancing wholly-owned programs for Respiratory Syncytial Virus (RSV), Chronic Spontaneous Urticaria (CSU), and Atopic Dermatitis (AD).
Key Financial Metrics
| Metric (in thousands) | Fiscal 2025 | Fiscal 2024 | Fiscal 2023 |
|---|---|---|---|
| Total Revenue | $65,324 | $67,635 | $79,204 |
| Net Loss | $(81,889) | $(116,045) | $(133,816) |
| Research & Development Expenses | $106,740 | $131,476 | $163,524 |
| General & Administrative Expenses | $43,933 | $57,850 | $52,887 |
| Cash, Cash Equivalents & Short-Term Securities | $188,864 | $248,186 | N/A |
| Net Cash Used in Operating Activities | $(19,272) | $(78,764) | $(103,154) |
| Liability Related to Sale of Future Royalties | $141,842 | $169,241 | $194,505 |
Note: Revenue consists entirely of royalty revenue from AbbVie. The company retains 45.5% of royalties earned after June 30, 2023, due to a 2023 sale of 54.5% of future royalties to OMERS.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3.4% to $65.3 million, driven by lower reported HCV sales by AbbVie compared to the prior year.
- Improved Net Loss: Net loss narrowed significantly by 29.4% to $81.9 million, primarily due to reduced operating expenses and a $33.8 million federal income tax refund received in April 2025.
- R&D Expense Reduction: R&D expenses decreased $24.7 million (18.8%) year-over-year. This was largely due to the timing of clinical trials in the RSV program (specifically the completion of Phase 2 studies) and a reduction in COVID-19 program costs.
- Immunology Investment: While total R&D decreased, spending on immunology programs (KIT and STAT6) increased by $10.2 million as the company advances these new therapeutic areas.
- Interest Expense: Interest expense decreased $3.3 million due to the paydown of the liability associated with the OMERS royalty sale agreement.
Guidance, Outlook, and Risks
Liquidity and Capital Resources: As of September 30, 2025, the company held $188.9 million in cash and short-term investments. Management believes this, combined with retained royalty cash flows and proceeds from a public offering completed in October 2025 (gross proceeds of ~$74.8 million), will fund operations into fiscal 2029.
Outlook and Pipeline Progress:
- RSV: Positive Phase 2b results were announced in September 2025 for zelicapavir in high-risk adults, showing faster symptom resolution and reduced hospitalization rates. The company is evaluating partnership opportunities to advance RSV programs.
- Immunology: The company is finalizing IND-enabling activities for EDP-978 (KIT inhibitor for CSU) with an expected IND filing in Q1 2026. IND-enabling activities for EPS-3903 (STAT6 inhibitor for AD) are underway with a target filing in H2 2026.
- HCV: MAVYRET received FDA approval in June 2025 as the first and only treatment for acute HCV infection.
Key Risks and Contingencies:
- Revenue Dependence: Future revenues are substantially dependent on AbbVie's sales of MAVYRET/MAVIRET, which face competition and declining HCV diagnosis rates.
- OMERS Agreement: 54.5% of future royalties (through June 2032) are paid to OMERS, subject to a cap of 1.42x the purchase price ($200 million).
- Patent Litigation: The company is appealing a District Court summary judgment ruling that invalidated its '953 Patent regarding Pfizer's Paxlovid. A new infringement action was filed in the European Union in August 2025.
- Manufacturing: Reliance on third-party manufacturers, including those in China, for active pharmaceutical ingredients poses supply chain risks.
Investor Verification Checklist
- AbbVie Sales Trends: Verify AbbVie's reported net sales of MAVYRET/MAVIRET to confirm the trajectory of Enanta's royalty revenue.
- OMERS Liability Cap: Monitor the aggregate payments made to OMERS to determine when the 1.42x cap ($284 million) might be reached, which would alter future cash flow retention.
- Partnership Status: Confirm progress on partnership discussions for the RSV programs (zelicapavir and EDP-323), as continued independent development requires significant capital.
- Patent Litigation Outcome: Track the appeal of the Pfizer patent invalidation ruling and the status of the new European Union lawsuit, as these impact potential future revenue streams and legal costs.
- IND Filings: Verify the timely submission of IND applications for EDP-978 (Q1 2026) and EPS-3903 (H2 2026) to assess the timeline for clinical data readouts.